...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Retrospective Multicentre Analysis of S.M.A.R.T. vs. Luminexx Nitinol Stent Implantation for Superficial Femoral Artery Lesions (REAL SL) Registry – 5 Years' Experience –
【24h】

Retrospective Multicentre Analysis of S.M.A.R.T. vs. Luminexx Nitinol Stent Implantation for Superficial Femoral Artery Lesions (REAL SL) Registry – 5 Years' Experience –

机译：S.M.A.R.T.的回顾性多中心分析与Luminexx镍钛诺支架植入治疗股浅动脉病变（REAL SL）–五年经验–

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: ?The nitinol stent has proven superior primary patency than balloon angioplasty in superficial femoral artery (SFA) lesions, but a systematic comparison of the patency of 2 different nitinol stents (S.M.A.R.T. and Luminexx) in patients with SFA lesions has not been done. Methods and Results: ?A multicenter, prospective database that included 511 consecutive patients who had undergone endovascular therapy with nitinol stenting for 638 limbs (S.M.A.R.T.: n=503; Luminexx: n=135) was retrospectively analyzed. Patency was assessed by duplex ultrasound. Outcomes were compared between the groups by the Kaplan-Meier and log-rank methods. To minimize the differences between each group, propensity-matched analysis was also performed. Stent fracture occurred in 11% (57/503) of the S.M.A.R.T. and 23% (31/135) of the Luminexx stents (P=0.0005). Despite a higher prevalence of chronic total occlusion (55% vs. 40%, P=0.002) and longer lesions (154±93mm vs. 135±71mm, P=0.03) in the S.M.A.R.T. group, there was no significant difference in patency for up to 5 years (P=0.50). When 119 lesions per group were assessed after propensity-matched analysis, the 5-year patency rate was 74% for the S.M.A.R.T. and 65% for the Luninexx stent (P=0.10). Conclusions: ?Despite a different stent fracture rate, there was no significant difference in terms of patency between the S.M.A.R.T. and Luninexx stents for up to 5 years. ( Circ J 2011; 75: 421-427)
机译：背景：？在股浅表动脉（SFA）病变中，镍钛诺支架的初次通畅性优于球囊血管成形术，但尚未对两种SFA病变患者的两种镍钛合金支架（S.M.A.R.T.和Luminexx）的通畅性进行系统比较。方法和结果：回顾性分析了一个多中心的前瞻性数据库，该数据库包括511名连续接受了638条肢体镍钛合金支架内血管内治疗的患者（S.M.A.R.T.：n=503;Luminexx：n=135）。通过双工超声评估通畅性。通过Kaplan-Meier和对数秩方法比较两组之间的结果。为了使每组之间的差异最小化，还进行了倾向匹配分析。 S.M.A.R.T.的11％（57/503）发生了支架断裂。和23％（31/135）的Luminexx支架（P = 0.0005）。尽管S.M.A.R.T.中慢性完全闭塞的患病率较高（55％比40％，P = 0.002）和更长的病变（154±93mm对135±71mm，P = 0.03）在长达5年的时间里，通畅性没有显着差异（P = 0.50）。通过倾向匹配分析评估每组119个病变后，S.M.A.R.T。的5年通畅率为74％。 Luninexx支架占65％（P = 0.10）。结论：？尽管支架的骨折率不同，但S.M.A.R.T.的通畅性无明显差异。和Luninexx支架长达5年。 （Circ J 2011; 75：421-427）

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号